Business
Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results
December 13 Program to Review FX-322 Phase 2b Study and Endpoints, Physician Demand for Interventions to Treat Sensorineural Hearing Loss and Market
About this update from Korro Bio, Inc.
[{"type":"text","content":"\nDecember 13 Program to Review FX-322 Phase 2b Study and Endpoints, Physician Demand for Interventions to Treat Sensorineural Hearing Loss and Market Opportunity\n\n LEXINGTON, Mass.--(BUSINESS WIRE)--\nFrequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it will host a virtual investor event on December 13, 2022, with a focus on FX-322, the Company’s lead hearing restoration candidate for acquired sensorineural hearing loss (SNHL). A Phase 2b study of FX-322 (FX-322-208) is fully enrolled with clinical results anticipated in the first quarter of 2023.\n\nAt the event, Company management will review the FX-322-208 study design, the patient populations targeted for enrollment, pre-specified speech perception endpoints, and the potential FX-322 commercial market opportunity. Key opinion leaders (KOLs) in auditory science and otolaryngology will provide insights on the potential impact of a pharmaceutical intervention for patients with SNHL. They will also discuss how a medicine for cochlear regeneration may fit with currently available hearing devices and the clinical significance of speech perception on overall hearing.\n\nEvent Details and Registration:\n\nThe webcast is scheduled for Tuesday, December 13, 2022, from 8:00 to 9:00 a.m. EST, and will include a live Q&A after the presentations. Following is the list of management and KOLs expected to participate:\n\n\nDavid L. Lucchino, Chief Executive Officer: Strategic Company overview and pipeline updates.\n\n\nKevin Franck, Ph.D., SVP, Strategic Marketing and New Product Planning: Cochlear restoration market development and the demand for new therapeutics.\n\n\nCarl LeBel, Ph.D., Chief Development Officer: FX-322 hearing restoration program and the clinical development path.\n\n\nChristina Runge, Ph.D., Professor of Otolaryngology and Communication Sciences, Medical College of Wisconsin: Challenges faced by individuals with speech perception and word discrimination deficits.\n\n\nAnthony Mikulec, MD, Professor of Otology & Neurotology at St. Louis University and SSM Health: Current treatment paradigms and the clinical opportunity to introduce pharmaceutical interventions for SNHL.\n\n\nTo register for the event, please clic...